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Abstract
L-2-Hydroxyglutaric (LGA) and D-2-hydroxyglutaric (DGA) acids are the characteristic metabolites accumulating in the
neurometabolic disorders known as L-2-hydroxyglutaric aciduria and D-2-hydroxyglutaric aciduria, respectively. Although
these disorders are predominantly characterized by severe neurological symptoms, the neurotoxic mechanisms of brain
damage are virtually unknown. In this study we have evaluated the role of LGA and DGA at concentrations ranging from
0.01 to 5.0 mM on various parameters of energy metabolism in cerebral cortex slices and homogenates of 30-day-old Wistar
rats, namely glucose uptake, CO2 production and the respiratory chain enzyme activities of complexes I to IV. DGA
significantly decreased glucose utilization (2.5 and 5.0 mM) by brain homogenates and CO2 production (5 mM) by brain
homogenates and slices, whereas LGA had no effect on either measurement. Furthermore, DGA significantly inhibited
cytochrome c oxidase activity (complex IV) (EC 1.9.3.1) in a dose-dependent manner (35^95%) at doses as low as 0.5 mM,
without compromising the other respiratory chain enzyme activities. In contrast, LGA did not interfere with these activities.
Our results suggest that the strong inhibition of cytochrome c oxidase activity by increased levels of DGA could be related to
the neurodegeneration of patients affected by D-2-hydroxyglutaric aciduria. ß 2002 Published by Elsevier Science B.V.
Keywords: L-2-Hydroxyglutaric acid; D-2-Hydroxyglutaric acid; Brain metabolism; Cytochrome c oxidase
1. Introduction
L-2-Hydroxyglutaric aciduria (LHGA) and D-2-hy-
droxyglutaric aciduria (DHGA) are rare neurometa-
bolic disorders biochemically characterized by tissue
accumulation and high urinary excretion of L-2-hy-
droxyglutaric acid (LGA) and D-2-hydroxyglutaric
acid (DGA), respectively [1^6].
LHGA was ¢rst described in 1980 by Duran and
colleagues [2] and has now been described in at least
50 patients. Patients with LHGA usually present
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with mental deterioration, seizures, pyramidal and
extrapyramidal symptoms and severe cerebellar dys-
function. Ataxia, tremor and choreiform movements,
as well as speech delay in infancy or childhood have
also been reported [4,7,8]. Although in most patients
symptoms presentation occurs in early to middle
childhood, a more severe form has been reported in
an infant which presented with hypotonia, apnoea
and convulsions shortly after birth [9]. An adult
form a¡ecting older patients has also been reported
[10]. Neuroimaging reveals cerebellar atrophy, pro-
gressive loss of myelinated arcuate ¢bres and alter-
ations in the basal ganglia. Besides the characteristic
high levels of LGA in plasma, CSF and urine, a few
a¡ected patients present increased concentrations of
lactate or Krebs cycle intermediates in CSF, plasma
or urine [4,9,11].
DHGA was ¢rst recognized by Chalmers and co-
workers in 1980, and has now been reported in at
least 25 patients [1,6]. It is clinically characterized by
at least two variants, a severe form with early-infan-
tile-onset encephalopathy, whose patients usually
present with seizures, hypotonia and poor develop-
ment, as well as enlarged frontal subarachnoid spaces
and subdural e¡usions and signs of cerebral delayed
maturation with subependymal cysts in the caudate
nucleus detected by MRI. The other variant is clin-
ically milder and more variable, presenting usually
with mental retardation, macrocephaly and hypoto-
nia. Delayed cerebral maturation, ventriculomegaly
and subependymal cysts are also observed by MRI.
Biochemically, besides the high excretion of DGA,
lactate and Krebs cycle intermediates are also found
in elevated amounts in the urine of a considerable
number of patients [5,6]. High excretion of DGA
also occurs in multiple acyl-CoA dehydrogenase de-
¢ciency (glutaric acidemia type II), which is due to a
defect of the electron transfer £avoprotein (ETP) or
of the mitochondrial enzyme ETF-ubiquinone oxido-
reductase [12].
Despite the intensive clinical investigation and the
large number of loading and fast tests, the underly-
ing biochemical defect of these disorders and the
origin of DGA and LGA have remained an enigma.
Initially L-2-hydroxyglutaric acid dehydrogenase and
D-2-hydroxyglutaric acid dehydrogenase de¢ciencies
were considered as potential causes of these diseases.
However, the activities of the enzymes were normal
or even increased in the liver of a¡ected patients,
suggesting that their accumulation may result from
a secondary pathway, rather than from the primary
substrate of the missing enzyme activity [3,4,13].
Likewise, the e¡ects of these acids on cell metabolism
are virtually unknown and await investigation.
Moreover, virtually nothing is known about the
pathophysiology of the neurological dysfunction of
DHGA and LHGA. However, considering that ele-
vated levels of lactate and/or Krebs cycle intermedi-
ates are observed in some patients a¡ected by these
disorders, it is conceivable that a primary or func-
tional mitochondrial defect or dysfunction may be
associated with these diseases.Therefore, in the
present study we investigated the in vitro e¡ects of
DGA and LGA on various parameters of energy
metabolism such as glucose utilization and CO2 for-
mation and on the enzyme activities of the respira-
tory chain complexes in cerebral cortex of young rats
in the hope to determine whether the acids could
compromise energy production in the brain. Skeletal
muscle from human beings were also used in some
experiments since, similarly to brain, this tissue has a
high amount of mitochondria and thus a high de-
mand of energy.
2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma Chem-
ical Co., St. Louis, MO, USA, except for the radio-
labeled compounds [U-14C]acetate and [U-14C]citrate
which were purchased from Amersham International
plc, UK.
2.2. Subjects
Thirty-day-old Wistar rats bred in our laboratory
were used. Rats had free access to a 20% protein
commercial chow and water and were kept in a
room with a 12:12-h light/dark cycle and tempera-
ture of 24 þ 1‡C. Animals were killed by decapitation
without anesthesia, the brains were immediately re-
moved and the cerebral cortex was dissected onto an
ice-cold glass plate. The experimental protocol was
approved by the Ethics Committee for animal re-
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search of the Federal University of Rio Grande do
Sul, Porto Alegre.
Skeletal muscle specimens obtained from normal
human individuals were also used for cytochrome c
oxidase activity determination. All subjects gave
written informed consent to participate in the study.
The research was approved by the Committee for
Human Research of Hospital de Cl|¤nicas de Porto
Alegre.
2.3. Tissue preparation
2.3.1. Cerebral cortex slice preparation
Brain cortex was cut to produce 400-Wm wide sli-
ces using a McIlwain chopper. Slices were pooled,
weighed and used for the glucose uptake and CO2
production assays.
2.3.2. Homogenate preparation
Rat cerebral cortex was homogenized (1:10, w/v)
in Krebs^Ringer bicarbonate bu¡er, pH 7.0 (glucose
uptake) or pH 7.4 (CO2 production), or in SETH
bu¡er, pH 7.4 (250 mM sucrose, 2 mM EDTA, 10
mM Trizma base, 50 UI ml31 heparin) (respiratory
chain enzyme activities). The homogenates were cen-
trifuged at 800Ug for 10 min and the supernatants
kept at 370‡C until used for enzyme activity deter-
mination. The maximal period between homogenate
preparation and enzyme analysis was always less
than 5 days.
Human skeletal muscle was homogenized in the
same way and the supernatants were used for the
determination of cytochrome c oxidase (COX) activ-
ity. The protein concentration in the supernatants
(brain and skeletal muscle) varied from 1.0 to 2.0
mg protein ml31.
2.4. Glucose utilization
Cerebral cortex slices (100 mg) or a corresponding
volume of homogenates (1:10, w/v) prepared in
Krebs^Ringer bicarbonate bu¡er, pH 7.0 (KRB)
from overnight-fasted animals were incubated in
the same bu¡er (in a total volume of 1 ml), contain-
ing 5.0 mM glucose and DGA or LGA (1^5 mM) in
a O2/CO2 (19:1) mixture in a metabolic shaker at
37‡C for 60 min. Flasks were ¢rstly pre-incubated
for 15 min (90 oscillations min31) in the absence of
glucose. Glucose was then added at the beginning of
incubation. Control experiments did not contain the
acids in the incubation medium [14]. Glucose was
measured by the glucose oxidase method [15] and
the uptake determined by subtracting the amount
after incubation from the total amount measured
before incubation.
2.5. CO2 production
Cerebral cortex slices (50 mg) or a corresponding
volume of homogenates (1:10, w/v) were added to
small £asks (11 cm3) containing 0.5 ml Krebs^Ringer
bicarbonate bu¡er, pH 7.4. Flasks were pre-incu-
bated in a metabolic shaker at 37‡C for 15 min (90
oscillations min31). After pre-incubation, 0.2 WCi [U-
14C]acetate and 0.5 mM of the unlabeled acetate
were added to the incubation medium. In some ex-
periments, 0.1 WCi [U-14C]citrate and 0.5 mM of the
unlabeled substrate were used. DGA or LGA (bu¡-
ered to pH 7.4) was added to the incubation medium
at ¢nal concentrations of 1.0, 2.5 or 5.0 mM. The
controls did not contain the acids. The £asks were
gassed with a O2/CO2 (95:5) mixture and sealed with
rubber stoppers and Para¢lm M. Glass center wells
containing a folded 65 mm/5 mm piece of Whatman
3 ¢lter paper were hung from the stoppers. After 60
min of incubation at 37‡C, 0.1 ml of 50% trichloro-
acetic acid was added to the medium and 0.1 ml of
benzethonium hydroxide was added to the center
wells with needles introduced through the rubber
stopper. The £asks were left to stand for 30 min to
complete CO2 trapping and then opened. The ¢lter
papers were removed and added to vials containing
scintillation £uid, and radioactivity was measured
[16].
2.6. Respiratory chain enzyme activities
The activities of citrate synthase (EC 4.1.3.7) and
of the respiratory chain enzyme complexes succinate-
DCIP-oxidoreductase (complex II) (EC 1.3.5.1) and
succinate:cytochrome c oxidoreductase (complex
II+CoQ+complex III) (EC 1.10.2.2) were determined
in brain cortex homogenates according to the meth-
od of Fischer et al. [17]. The activity of cytochrome c
oxidase (complex IV) (COX) (EC 1.9.3.1) was mea-
sured according to Rustin et al. [18], whereas those
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of NADH:cytochrome c oxidoreductase (complex
I+CoQ+complex III) (EC 1.6.5.3) and ubiquinol
cytochrome c oxidoreductase (complex III) (EC
1.10.2.2) were assayed according to the method de-
scribed by Schapira et al. [19]. Experimental groups
contained various concentrations of LGA or DGA
(1, 2.5 and 5 mM). Control groups did not contain
any acid in the incubation medium.
2.7. Protein determination
Protein was measured by the method of Lowry et
al. [20] using bovine serum albumin as standard.
2.8. Statistical analysis
Unless otherwise stated, results are presented as
means þ standard error of the mean. Data concern-
ing glucose utilization, CO2 production and the ac-
tivities of the respiratory chain enzyme complexes
were analyzed by one-way analysis of variance (AN-
OVA) followed by the post-hoc Duncan multiple
range test when F was signi¢cant. The Student t-
test for paired samples was also used for comparison
of two means. Di¡erences between the groups were
rated signi¢cant at a probability error of less than
0.05.
Fig. 2. E¡ect of D-2-hydroxyglutaric acid (DGA) and L-2-hy-
droxyglutaric acid (LGA) on in vitro CO2 production from [U-
14C]acetate (Wmol h31 (g tissue)31) by cerebral cortex homoge-
nates of 30-day-old rats. Values are mean þ S.E.M. for n = 4^7
per group, and are expressed as percentage of controls.
*P6 0.05, compared to controls (Duncan multiple range test).
Fig. 1. E¡ect of D-2-hydroxyglutaric acid (DGA) on in vitro
glucose uptake (Wmol h31 (g tissue)31) by cerebral cortex of 30-
day-old rats. Values are mean þ S.E.M. for n = 4^7 per group.
*P6 0.05, **P6 0.01 compared to controls (Duncan multiple
range test). (A) Slices; (B) homogenates.
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3. Results
We ¢rst determined the e¡ect of DGA (Fig. 1) and
LGA (Fig. 2), at concentrations varying from 1 to
5 mM, on glucose utilization by cerebral cortex
slices and homogenates of 30-day-old rats. DGA at
concentrations of 2.5 mM and higher signi¢cantly
reduced the utilization of glucose by the cerebral
homogenates (F(3,14) = 5.5663; P = 0.0143), but not
by the cerebral cortex slices (F(3,23) = 0.2354;
P = 0.8706) (Fig. 1). LGA (5 mM) had no e¡ect on
this parameter either in slices (t(7) = 0.45; P = 0.671)
or in homogenates (t(7) = 0.849; P = 0.424) (results
not shown).
Fig. 2 shows the in vitro CO2 production from [U-
14C]acetate in rat cerebral cortex homogenates in the
presence of 1.0, 2.5 or 5.0 mM DGA (Fig. 2A) or
LGA (Fig. 2B). Values are expressed as percentage
of controls. CO2 production ranged from 81 to 156
Wmol h31 (mg tissue)31 in the control group. It
can be seen that 5 mM DGA signi¢cantly reduced
CO2 production in homogenates (F(3,27) = 3.1537;
P = 0.0433), whereas LGA had no e¡ect (F(3,15) =
0.6739; P = 0.5845). Fig. 3 shows the in vitro CO2
production from [U-14C]acetate in rat cerebral cortex
slices in the presence of 5.0 mM DGA (Fig. 3A) or
LGA (Fig. 3B). DGA signi¢cantly reduced CO2
production, whereas LGA had no e¡ect (F(2,11) =
4.4614; P = 0.0451).
We also examined the e¡ect of 5 mM LGA and
DGA on the in vitro CO2 production from
[U14C]citrate by cerebral cortex slices (Fig. 4). In
these experiments we also used 5 mM malonate
(MA), a classical and potent succinate dehydroge-
nase inhibitor. The results showed that malonate
and DGA signi¢cantly inhibited CO2 production,
whereas LGA caused no e¡ect (F(3,11) = 8.1022;
P = 0.0083).
Next, we investigated the e¡ect of DGA and LGA
on the activities of the respiratory chain enzyme
complexes in homogenates of rat brain cortex.
DGA strongly reduced the activity of cytochrome c
oxidase (COX) (F(7,43) = 51.1114; P = 0.00001) in a
dose-dependent way, whereas the activities of com-
plex I+III (F(3,15) = 0.2127; P = 0.8856), complex II
(F(3,23) = 0.1130; P = 0.9392), succinate dehydroge-
nase (SDH) (F(3,23) = 0.3832; P = 0.7662), complex
II+III (F(3,15) = 2.4241; P = 0.1163), and complex
III (F(2,23) = 0.9773; P = 0.4231) were not a¡ected
by the acid (Fig. 5). In contrast, LGA did not alter
these activities (complex I+III: F(3,15) = 0.04435;
P = 0.7262; complex II: F(3,23) = 0.2242, P = 0.8784;
SDH: F(3,31) = 0.499, P = 0.985; complex II+III,
F(3,15) = 0.1529; P = 0.9258; complex III F(3,15) =
0.3385; P = 0.7999; complex IV: F(3,15) = 0.190;
P = 0.9962) (results not shown).
The concentration of DGA required to inhibit 50%
Fig. 4. E¡ect of D-2-hydroxyglutaric acid (DGA), L-2-hydroxy-
glutaric acid (LGA) and malonate (MA) on in vitro CO2 pro-
duction from [U-14C]citrate (Wmol h31 (g tissue)31) by cerebral
cortex slices of 30-day-old rats. Values are mean þ S.E.M. for
n = 3 per group, and are expressed as percentage of controls.
*P6 0.05, compared to controls (Duncan multiple range test).
Fig. 3. E¡ect of D-2-hydroxyglutaric acid (DGA) and L-2-hy-
droxyglutaric acid (LGA) on in vitro CO2 production from [U-
14C]acetate (Wmol h31 (g tissue)31) by cerebral cortex slices of
30-day-old rats. Values are mean þ S.E.M. for n = 4 per group,
and are expressed as percentage of controls. *P6 0.05, com-
pared to controls (Duncan multiple range test).
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Fig. 5. E¡ect of D-2-hydroxyglutaric acid (DGA) on the activities (nmol min31 (mg protein)31) of the respiratory chain enzyme com-
plexes in cerebral cortex homogenates of 30-day-old rats. Values are mean þ S.E.M. for n = 4^9 independent experiments per group of
the respiratory chain complexes activities measured in cerebral cortex homogenates in the presence or absence of the metabolites.
**P6 0.01 compared to controls (Duncan multiple range test).
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of COX activity in cerebral cortex of rats was mea-
sured as the IC50 [21]. The data indicated an
IC50 = 0.314 þ 0.061 mM (mean þ S.D.).
In order to test whether the signi¢cant reduction
of COX activity caused by DGA was due to a non-
speci¢c e¡ect of D-enantiomers, we also tested the
e¡ect of 5 mM D-2-hydroxy-3-methylvaleric acid
(HMVA), a compound with a molecular mass similar
to that of DGA on this activity. The acid did not
alter COX activity in homogenates of rat cerebral
cortex (t(6) = 1.09; P = 0.319) (results not shown).
The next step was to investigate whether the inhi-
bition of COX activity veri¢ed in rat brain also oc-
curs in human tissues. Thus, the e¡ect of 5 mM
DGA on COX activity from human skeletal muscle
homogenates was examined. We observed that the
acid signi¢cantly inhibited COX activity in skeletal
muscle (t(10) = 3.786; P = 0.004) (Fig. 6).
The kinetics of the interaction of DGA with COX
in homogenates from cerebral cortex was also deter-
mined [22]. The Lineweaver^Burk double-reciprocal
plot was analysed over a range of cytochrome c con-
centrations (0.008^0.05 WM) in the absence or pres-
ence of DGA (0.5^2.5 mM). The data indicate that
the inhibition of COX activity by DGA is uncompe-
titive (Fig. 7). The Km calculated was 0.0539 þ 0.011
mM (mean þ S.D., n = 3). The Ki value (the dissoci-
ation constant of the enzyme^substrate^inhibitor
complex) was calculated by the method of Dixon
[21], which provides a simple way of determining
the inhibition constant (Ki) for uncompetitive inhib-
itors. The Ki value calculated was 0.226 þ 0.022 mM
for DGA (mean þ S.D., n = 5).
4. Discussion
High amounts of DGA and LGA accumulate in
DHGA and LHGA, respectively. Although severe
neurological symptoms and structural brain abnor-
malities are frequently found in these neurometabolic
diseases, very little is known about the pathophysio-
Fig. 7. Kinetic analysis of the inhibition of cytochrome c oxidase from cerebral cortex of rats by D-2-hydroxyglutaric acid. The graph
shows a double reciprocal plot of cytochrome c oxidase for cytochrome c concentrations (0.008^0.025 WM) ([S]) in the absence (8,
controls) and in the presence of 0.5 (b), 1.0 (O), 1.5 (U) and 2.5 (*) mM D-2-hydroxyglutaric acid ([I]). The inset shows the Dixon
plot for Ki determination. All experiments were repeated at least three times and similar results were obtained. Data presented are
representative of one experiment.
Fig. 6. The e¡ect of D-2-hydroxyglutaric acid (DGA) on cyto-
chrome c oxidase activity (nmol min31 (mg protein)31) from hu-
man skeletal muscle. Values are mean þ S.E.M. for n = 6 per
group. **P6 0.01 compared to controls (Student t-test).
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logical mechanisms underlying the neurological dys-
function of DHGA and LHGA [5,23]. The under-
standing of the biochemical alterations in brain
may possibly contribute to a better therapeutic man-
agement and consequently to higher survival rates
for the a¡ected patients.
The present study was undertaken to evaluate the
in£uence of high concentrations of DGA and LGA
on some biochemical parameters of energy metabo-
lism in rat brain. We ¢rstly observed that DGA de-
creased brain glucose utilization in cerebral cortex
homogenates, but not in cortical slices, and that
LGA had no e¡ect on this parameter. The lower
rate of glucose utilization by homogenates may re-
£ect a decreased Krebs cycle activity. Moreover, the
lack of e¡ect of DGA with slices may be due to a
lower penetration of the metabolite to all of the cells
in the slice. In this context, the next set of experi-
ments were designed to investigate the activity of the
Krebs cycle by measuring CO2 production from ace-
tate. A signi¢cant reduction of CO2 production in
brain homogenates and slices was detected due to
the presence of DGA in the incubation medium,
whereas LGA had no e¡ect on this parameter.
Although we do not know how DGA crosses cell
membranes, a possible competition between DGA
and acetate through the same membrane transporter
(monocarboxylic carrier) may reduce CO2 produc-
tion from [U14C]acetate. However, this is unlikely
since CO2 generation from citrate, which uses the
tricarboxylic carrier to enter mitochondria, was also
blocked by DGA. Thus, the data are indicative that
the inhibitory action of DGA is probably secondary
to a blockage of the Krebs cycle and/or the respira-
tory chain.
In this context, we veri¢ed that DGA strongly in-
hibited COX (complex IV) activity in a concentra-
tion-dependent manner, whereas the other activities
of the respiratory chain were not changed by the
metabolite. On the other hand, LGA did not alter
the respiratory chain complex activities studied. The
results indicate that DGA is an inhibitor of only one
enzyme of the electron transfer respiratory chain in-
volved in the oxidative phosphorylation and respon-
sible for most energy produced in the cell. The ki-
netic analysis of the e¡ects of DGA on COX activity
indicated an uncompetitive inhibition. The Ki value
obtained for the inhibition of COX by DGA was of
the millimolar order. Therefore, it is likely that sup-
pression of COX activity by DGA is the primary
cause of the reduction of both glucose uptake and
CO2 production (Krebs cycle) observed in the
present study. Further studies are clearly required
to verify the in vivo e¡ect of DGA on COX activity
and this investigation is currently in progress in our
laboratory.
Furthermore, the observations that LGA did not
interfere with the parameters studied and that D-2-
hydroxymethylvaleric acid, a D-isomer of molecular
mass similar to that of DGA, caused no alteration of
COX activity point to a speci¢c e¡ect of DGA,
rather than a nonspeci¢c action due to acidic or to
D-enantiomer compounds. As regards LGA, our re-
sults are in agreement with a previous report demon-
strating that the activities of complexes I to IV of the
respiratory chain are normal in liver and muscle bi-
opsies from patients with LHGA, indicating that the
sustained tissue elevation of LGA does not provoke
inhibition of these activities [4].
We also veri¢ed in the present study that DGA
inhibits COX activities in human skeletal muscle ho-
mogenates, and this is not surprising since, due to its
critical importance for life support, in general the
chemical structure of cytochrome oxidase was well
preserved along evolution.
Cytochrome c oxidase (COX; EC 1.9.3.1) or com-
plex IV, the last component of the respiratory chain,
catalyses the transfer of electrons from cytochrome c
to molecular oxygen. It consists of 13 subunits, 10 of
which are encoded by nuclear DNA [24]. A defect in
this complex causes an inability to produce energy
aerobically and results in the accumulation of lactic
acid. The tissues that are more dependent on aerobic
metabolism, such as brain, muscle and heart, are
more likely to be a¡ected in these disorders. This is
in line with the fact that COX de¢ciency usually
causes an encephalopathy or a myopathy, although
the most common clinical presentation is encephalo-
pathy [25^33].
The regulation of the rate of respiration and ATP
synthesis was previously thought to be only due to
the electrochemical proton gradient across the inner
mitochondrial membrane according to the chemios-
motic hypothesis [34]. More recently, another mech-
anism of respiratory control was attributed to the
allosteric inhibition of COX at high intramitochon-
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drial ATP/ADP ratios [35^37]. In a recent report,
Kadenbach and colleagues [38] demonstrated a re-
versible and cAMP-dependent phosphorylation of
nuclear-coded subunits of COX at high ATP levels
causing its inhibition and hypothesized that this may
represent a general mechanism of energy metabolism
control based on variable e⁄ciency of energy trans-
duction in COX and on the turning on and o¡ of
respiratory control via the intramitochondrial ATP/
ADP ratio.
Although neurological symptoms are common in
primary mitochondrial disorders, very little is known
about the in£uence of the metabolites accumulating
in neurodegenerative disorders on the activities of the
respiratory chain complexes. In the present study we
demonstrated that D-hydroxyglutaric acid strongly
inhibits COX activity in brain of young animals.
The degree of this inhibition ranged from 45% to
90% according to the concentration of DGA used
in the assays (0.5^5 mM). The question which must
be raised is whether this extent of inhibition could
compromise energy production. A recent report
showed that the control of COX £ux is tightly regu-
lated in human skeletal muscle in vivo with impor-
tant implications for mitochondrial myopathies [39].
These investigators demonstrated that signi¢cant re-
ductions of the respiratory £uxes are evident even at
a low degree of inhibition of the isolated COX. They
observed signi¢cant e¡ects on the £ux control coef-
¢cient and the COX reserve capacity in samples hav-
ing 10^50% deleted mtDNA, re£ected by a decline in
COX activity and heme aa3 content, and presumed
that these ¢ndings might possibly explain the patho-
logical phenotype occurring in individuals carrying a
low proportion of mutant mtDNA in susceptible tis-
sues. All this indicates a rate limitation of oxidative
phosphorylation by COX. Therefore, the degree of
inhibition (45^90%) found in the present study prob-
ably leads to blockage of the aerobic glycolytic path-
way and to energy deprivation. Therefore, it is
tempting to speculate that energy deprivation may
be related to the symptomatology and brain damage
seen in patients a¡ected by DHGA.
In the present study, signi¢cant inhibition of COX
activity was achieved with 0.5 mM DGA, which is
within the blood circulating (46^757 Wmol l31) levels
of DGA in patients a¡ected by DHGA [5,6].
Although the brain concentrations of DGA in these
patients are yet unknown, we cannot exclude that
higher intracerebral concentrations of DGA may be
attained in this neurometabolic disease, as possibly
occurs in other organic acidemias so-called ‘cerebral’
organic acidemias whose symptoms are predomi-
nantly or almost exclusively neurologic [40]. There-
fore, if these results can be extrapolated to the
human condition, it is conceivable that this concen-
tration (0.5 mM) may a¡ect the respiratory chain
£ux in tissues of these patients.
The molecular defect of DHGA has not been es-
tablished yet. It has been proposed that D-2-hy-
droxyglutaric aciduria could be due to a primary
mitochondrial defect, with a separate ETF-linked of
ETF-ubiquinone oxireductase-linked dehydrogenase
being the molecular underlying defect [5]. Although
tissue accumulation of DGA is the biochemical hall-
mark of D-hydroxyglutaric aciduria, some of the
documented patients excrete increased amounts of
lactate and citric acid cycle intermediates or dicar-
boxylic acids, pointing to a primary or functional
mitochondrial dysfunction [6]. The present ¢ndings
point to a secondary mitochondrial respiratory chain
dysfunction caused by the metabolite which most
accumulates in this disorder. In this context, the el-
evation in the levels of Krebs cycle intermediates
found in some of the a¡ected patients may occur
secondarily to the blockage of the respiratory chain
electron £ux leading to an increase of NADH and
FADH2 concentrations. Increase of these reduced
nucleotides may possibly lead to inhibition of al-
pha-ketoglutaric acid and succinate dehydrogenases
and consequently of their precursors alpha-ketoglu-
tarate and succinate. Lactate may also be increased
because of the high NADH/NAD ratio. In this con-
text, it would be important to determine whether the
DGA levels are more elevated in patients excreting
or accumulating these intermediates.
Now concerning to the neuronal degeneration in
DHGA, lack of energy might compromise the syn-
thesis of neurotransmitters (acetylcholine, glutamate,
aspartate and GABA) from citric acid intermediates
[41] and lipid synthesis in brain which could cause
serious neurological damage. This may be the case
for DHGA where the patients have demyelination
and cerebral cortical atrophy [5].
On the other hand, our present ¢ndings of im-
paired mitochondrial energy production in brain
BBADIS 62073 20-12-01
C.G. da Silva et al. / Biochimica et Biophysica Acta 1586 (2002) 81^91 89
caused by DGA may lead to activation of the
NMDA receptors, even at normal concentrations of
glutamate in the synaptic cleft, by a reduction of the
resting membrane potential, inducing a release of the
voltage-dependent Mg2 block of the channel result-
ing in calcium in£ux and eventually cell death (slow-
onset excitotoxicity) [42]. It should also be stressed
that lack of energy may cause a de¢cient glutamate
uptake by glial cells and by neurons, leaving more
neurotransmitter in the cleft.
In conclusion, although the biochemical defect of
DHGA is still unknown, it is possible that a reduc-
tion of COX activity caused by DGA as found in the
present study may be related to the neurodegenera-
tion of patients a¡ected by DHGA. Inhibition of this
activity could also explain the elevation of some of
the Krebs cycle intermediates and lactate in the body
£uids of some of these patients. It is also interesting
to point out that hypotonia and myocardiopathy,
commonly seen in COX de¢ciency, are frequently
observed in DHGA patients with the early severe
form. On this basis, it is possible that some of our
results may be relevant to the understanding of the
biochemical alterations leading to neurologic deteri-
oration in these patients.
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